American Society of Hirudotherapy

Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis

Wieruszewski PM, Macielak SA, Nei SD, Moman RN, Seelhammer TG, Nabzdyk CGS, Gerberi DJ, Mara KC, Hooten WM, Wittwer ED (2022) · ASAIO Journal · n=0

RCT evidence detailTrial reference

Study Profile

Design
systematic review and meta-analysis of 6 retrospective observational studies (5 meta-analyzable)
Sample size (n)
0
Intervention
Bivalirudin anticoagulation in adult ECMO
Comparator
Heparin anticoagulation in adult ECMO
Primary endpoint
Circuit-related thrombosis, mortality, major bleeding events
Primary result
Heparin associated with more circuit-related thrombosis (OR 2.05, 95% CI 1.25-3.37, p=0.005) and higher mortality (OR 1.62, 95% CI 1.19-2.21, p=0.002) vs bivalirudin; no significant difference in major bleeding (OR 1.83, p=0.33)
Follow-up duration
ECMO run + hospital discharge

Key Findings

  • Mayo Clinic-led methodologically rigorous synthesis
  • Heparin associated with 2-fold higher circuit thrombosis vs bivalirudin
  • 62% higher mortality signal with heparin
  • No significant difference in major bleeding events
  • Uses ROBINS-I risk-of-bias tool for transparency

Limitations

  • All 6 studies retrospective observational
  • Significant heterogeneity in bleeding endpoint (I²=82.7%)
  • Patient selection bias likely
  • Confidence intervals broad for some outcomes
  • Not applicable to whole-leech hirudotherapy

Clinical Implications

Wieruszewski 2022 contributes adult-specific evidence to the bivalirudin ECMO landscape. For ASH, this meta-analysis demonstrates how rigorous methodology applied to retrospective data can produce robust signals for the synthetic thrombin inhibitor pathway, distinct from the K040187 device-leech US clinical practice. The thrombosis and mortality signals strengthen the case for prospective RCT confirmation.

Related Trials

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.